3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
39
Neoplasm Metastasis
6
Neoplasms
3
Neoplasms by Site
2
Melanoma
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Meningioma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer Not Immediately Operated
1
Interventions
Imatinib Mesylate
6
Sunitinib
4
ripretinib
2
regorafenib
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
trastuzumab deruxtecan
1
pemigatinib
1
olverembatinib
1
envafolimab
1
atezolizumab
1
apatinib
1
Temozolomide
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Midazolam
1
Laparoscopy
1
Ipilimumab
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Biopsy
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
ribociclib
×
90 days
×
Clear all
No trials found.